Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Merck
Moodys
Medtronic

Last Updated: September 26, 2022

SORILUX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Sorilux patents expire, and what generic alternatives are available?

Sorilux is a drug marketed by Mayne Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-eight patent family members in thirteen countries.

The generic ingredient in SORILUX is calcipotriene. There are twelve drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the calcipotriene profile page.

Summary for SORILUX
International Patents:28
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 45
Clinical Trials: 5
Patent Applications: 5,506
Drug Prices: Drug price information for SORILUX
What excipients (inactive ingredients) are in SORILUX?SORILUX excipients list
DailyMed Link:SORILUX at DailyMed
Drug patent expirations by year for SORILUX
Drug Prices for SORILUX

See drug prices for SORILUX

Recent Clinical Trials for SORILUX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Skin Sciences, PLLCPhase 4
Mayne Pharma International Pty LtdEarly Phase 1
Tulane UniversityEarly Phase 1

See all SORILUX clinical trials

Pharmacology for SORILUX

US Patents and Regulatory Information for SORILUX

SORILUX is protected by five US patents and two FDA Regulatory Exclusivities.

Patents protecting SORILUX

Vitamin formulation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS

Vitamin formulation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER

Vitamin formulation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS

Vitamin formulation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER

Vitamin formulation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER

FDA Regulatory Exclusivity protecting SORILUX

NEW PATIENT POPULATION
Exclusivity Expiration: See Plans and Pricing

NEW PATIENT POPULATION
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mayne Pharma SORILUX calcipotriene AEROSOL, FOAM;TOPICAL 022563-001 Oct 6, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Mayne Pharma SORILUX calcipotriene AEROSOL, FOAM;TOPICAL 022563-001 Oct 6, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Mayne Pharma SORILUX calcipotriene AEROSOL, FOAM;TOPICAL 022563-001 Oct 6, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Mayne Pharma SORILUX calcipotriene AEROSOL, FOAM;TOPICAL 022563-001 Oct 6, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SORILUX

See the table below for patents covering SORILUX around the world.

Country Patent Number Title Estimated Expiration
Brazil 9913154 Composição de musse See Plans and Pricing
European Patent Office 1872776 Composition de mousse (Mousse composition) See Plans and Pricing
Japan 2002524490 See Plans and Pricing
New Zealand 563560 Vitamin formulation for treating a dermatological skin disorder See Plans and Pricing
Australia 760153 See Plans and Pricing
Poland 2526930 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Baxter
McKinsey
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.